View our most recent call for papers: https://pubs.lib.umn.edu/index.php/innovations/article/view/3375
Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer’s Disease
Connie Yoon, Corey Groff, Olivia Criss
2024-03-18
Thuy Chinh Kieu, Kevin Look
2023-09-13
After The QALY: Training for a New Start Paradigm in Health Technology Assessment
Paul C Langley, Elliott M Sogol
2023-03-29
Patient-Centered Core Impacts Sets (PC-CIS): What They Are and What They Are Not
Eleanor M. Perfetto, Suz Schrandt, Omar A. Escontrías, Laurie B. Burke
2023-02-24
Rasch Measurement and Patient Reported Value Claims: A Primer for Hemophilia
Paul C Langley
2022-12-16
Evidentiary Standards for Patient-Centered Core Impact (PC-CIS) Value Claims
Paul C Langley
2022-10-25
Formulary Submissions: Value Claims, Protocols and Outcomes Based Contracting in Rare Disease
Paul Langley
2022-10-03
Use of an Innovative Pharmaceutical Class Scoring Tool for Prioritized Annual Formulary Review
Holly Sheldon, Audrey Kostrzewa, Shannon Werner, Terry Audley, Adam Biggs, Taylor Mancuso, Mary Frances Picone
2022-06-15
Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma
Paul C Langley
2022-05-24
Bayarmagnai Weinstein, Bogdan Muresan, Sara Solano, Antonio Vaz de Macedo, YoonJung Lee, Yu-Chen Su, Yeseul Ahn, Gabriela Henriquez, Christina Carmago, Gwang-Jin Kim, David O. Carpenter
2021-11-19
Outcomes of Alvimopan Use in Laparoscopic Intra-abdominal Surgery: A Retrospective Review
Aamir A. Kokan, Sahil Sheth, Katherine Rogers
2021-11-03
A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis
Paul C. Langley
2021-10-25
A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis
Paul C. Langley
2021-10-05
Stephen P McKenna, Alice Heaney, Paul C Langley
2021-05-11
Fundamental Measurement: The Need Fulfilment Quality of Life (N-QOL) Measure
Paul C. Langley, Stephen P. McKenna
2021-04-09
Let a Thousand Models Bloom: ICER Analytics Opens the Floodgates to Cloud Pseudoscience
Paul Langley
2021-01-20
Value Assessment in Cystic Fibrosis: ICER’s Rejection of the Axioms of Fundamental Measurement
Paul Langley
2020-05-14
Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies
Paul Langley
2019-12-30
Yoon Jung Lee, Kayla Leigh Money, Amber Elliott
2019-07-05
A Practice Based Behavioral Health Management Registry (BHMR): Implementation, Structure and Content
Paul C Langley
2019-04-22
CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER)
Paul Langley
2018-11-20
Blockchains, Formulary Evaluations and Health Technology Assessment
Paul Langley, Robert E Martin
2018-11-20
If You Build it Will They Come? Patients, Providers and Blockchains in Health Technology Assessment
Paul Langley, Robert E Martin
2018-11-20
Paul Langley, Robert E Martin
2018-11-20
Alternative Facts and the ICER Proposed Policy on Access to Imaginary Pharmacoeconomic Worlds
Paul Langley
2018-04-17
Paul C. Langley
2017-10-12
Paul C Langley, Taeho Greg Rhee
2017-05-19
Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
Paul C Langley, Dr
2017-05-16
HAS Should Not Be NICE: Rejecting Imaginary Worlds in the French Technology Assessment Guidelines
Paul C Langley
2017-01-30
Denkbeeldige Wereld: The New Dutch Guidelines for Economic Evaluations in Healthcare
Paul C Langley
2017-01-10
Paul C Langley
2016-11-23
Next Generation Sequencing Claims in Precision Medicine: Questions a Formulary Committee Should Ask
Paul C Langley
2016-11-11
Cost-Effectiveness and Formulary Evaluation: Imaginary Worlds and Entresto Claims in Heart Failure
Paul C Langley
2016-09-09
Paul C Langley, Taeho Greg Rhee
2016-07-12
Paul C Langley, Taeho Greg Rhee
2016-07-08
Paul C Langley, Taeho Greg Rhee
2016-07-08
Supporting Formulary Decisions: The Discovery of New Facts or Constructed Evidence?
Paul C Langley
2016-07-08
Modeling Imaginary Worlds: Version 4 of the AMCP Format for Formulary Submissions
Paul C Langley
2016-07-05
Greater Expectations for Pharmaceutical Value: Better Care, Healthier People, Smarter Spending
Jon C. Schommer, Brian Isetts
2016-07-01